Introduction {#s0001}
============

By April 24, 2020, there were 2,626,321 confirmed and 181,938 deaths cases of COVID-19 globally.[@cit0001] It is important that understood the effect of novel coronavirus on microbial composition on invaded mucosa for avoiding secondary infection. In recent year, next generation sequencing (NGS) technologies provide an increasingly important method for detecting microbial composition and pathogen in human.[@cit0002]

Methods {#s0002}
=======

In our hospital, 44 novel coronavirus infection patients (severe/critical: N = 8, non-severe: N = 36) were examined by NGS of nasopharyngeal test paper to observe the effect of novel coronavirus infection on the microbial composition in upper airway. And the demographics and clinical characteristics of these 44 COVID-19 patients were collected and analyzed. The DNA libraries were sequencing using the BGISEQ-100 platform from The Beijing Genomics Institute. Species information of suspected pathogenic microorganisms can be obtained through comparison of microbial database and intelligent algorithm analysis. We can identify 12,593 pathogenic microorganisms including bacteria, fungi, viruses, parasites, mycoplasma/chlamydia accurately. Statistical analysis was performed using Statistical Package for Social Science (SPSS) Version 17.0. Measurement data was expressed as mean ± standard deviation. Continuous variables were compared using independent-sample *t*-test, whereas the rank sum test was used for nonparametric data. P \<0.05 was considered statistically significant.

Results {#s0003}
=======

Demographics and Clinical Characteristics of COVID-19 Patients {#s0003-s2001}
--------------------------------------------------------------

Compared with non-severe patients, older of age, higher proportion of fever and fatigue, more basic diseases, more involved lung leaves, lower white blood cells, lower lymphocytes, decreased CD3 + T cells and subsets groups, but increased CRP were shown in severe/critical patients (P\<0.05, [Table 1](#t0001){ref-type="table"}). Specially, decreased CD3 + T cells and subsets groups were risk factors for secondary infection.Table 1Demographics and Clinical Characteristics of COVID-19 PatientsCharacteristicTotal (n = 44)Severe/Critical (n = 8)Non-Severe (n = 36)p valueAge, years54(3--77)62.5(54--77)44(3--71)0.008\* Gender Male21(47.7)5(62.5)16(44.4)0.35 Female23(52.3)3(37.5)20(45.6)**Signs and symptoms** Fever29(65.9)7(87.5)22(61.1)0.15 Cough18(40.9)3(37.5)15(41.7)0.83 Fatigue5(11.4)3(37.5)2(5.5)0.01\* Nasal discharge2(4.5)0(0)2(5.5)0.49 Pain (headache/sore throat/muscle aches, etc)9(20.4)2(25)7(19.4)0.72 T, °C37.0(36.5--37.8)37.7(37.3--38.0)36.8(36.5--37.7)0.04\* Underlying diseases(N/Y)16(36.4)5(62.5)11(30.5)0.09 Circulatory diseases (hypertension, coronary heart disease)7(15.9)2(25)5(13.9)0.44 Respiratory basic diseases (chronic bronchitis, lung cancer)3(6.8)2(25)1(2.8)0.02\* Endocrine system basic diseases (diabetes)3(6.8)2(25)1(2.8)0.02\* Other systemic diseases (fractures, cerebral infarction, etc.)5(11.4)1(12.5)4(11.1)0.91**Laboratory findings** White blood cell count, ×109/L4.61(3.67--6.48)3.52(3.14--4.59)4.82(3.83--6.56)0.04\* Lymphocyte count, ×109/L1.60 (1.08--2.13)0.85(0.45--1.46)1.76(1.36--2.46)0.001\* Neutrophil count, ×109/L2.30(1.79--3.47)2.08(1.30--3.34)2.36(1.88--3.61)0.38 Monocyte count, ×109/L0.47(0.37--0.66)0.34(0.26--0.52)0.49(0.40--0.71)0.06 NLR1.78(0.4--9.38)2.16(0.74--9.38)1.70 (0.40--5.68)0.025\* PCT2(4.5)1(12.8)1(2.8)0.23 CRP, mg/L2.45(0.56--7.62)22.0(8.68--42.5)1.15(0.48--5.06)0.001\* CD3(+) T lymphocytes,/ul1057(742.8--1561)565 (226.0--794.5)1162(891.3--1734)0.001\* CD3(+)CD4(+) T lymphocytes,/ul579(408.3--831.5)325(174.5--483.8)631.5(449.8--842.5)0.006\* CD3(+)CD8(+) T lymphocytes,/ul355(263.8--514.5)159(64.5--281.8)457.5(318.8--553.0)0.0002\* PaO2, mmHg99.9(86.6--105.0)91.1(75.7--101.2)101.0(89.1--105.3)0.12**CT imaging features** One or both lungs2(0--2)2(1--2)1(0--2)0.02\* Number of lung lobes (0--5)2next (0--5)5(1--5)1(0--5)0.001\* Ground glass lesions29(65.9%)7(87.5%)22(61.1%)0.15 Consolidation7(15.9%)3(37.5%)4(11.1%)0.06 Bronchial abnormalities4(9.1%)2(25%)2(5.5%)0.08 Mediastinal lymph node enlargement1(2.3%)1(12.5%)0(0)0.04\* Pleural effusion1(2.3%)1(12.5%)0(0)0.04\*[^2][^3]

The Microbial Composition of Upper Airway in COVID-19 Patients {#s0003-s2002}
--------------------------------------------------------------

In these nasopharyngeal test paper samples, 38 kinds of bacteria, 10 kinds of viruses except severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), nine kinds of fungi and three kinds of atypical pathogens had been found. The most common bacteria detected in upper airway in these patients were *Haemophilus* (40.9%), *Corynebacterium* (40.9%), *Prevotella* (36.36%), *Staphylococcus* (34.09%), *Moraxella* (22.72%), *Neisseria* (22.72%), *Streptococcus* (20.45%), *Megaphaera* (20.45%), *Pediococcus* (18.18%), and *Dolosigaranulum* (15.91%) ([Figure 1A](#f0001){ref-type="fig"}). *Human herpes virus* and *Torque teno virus* were the main viruses detected in nasopharyngeal test paper, but no *Influenza virus* was found. The most common viruses were *Human gamma herpesvirus 4* (38.6%) and *Human beta herpesvirus 7* (38.6%), and the other viruses were less than 10% ([Figure 1B](#f0001){ref-type="fig"}). *Candida* (36.36%) was the main fungus found in upper airway of patients, and *Aspergillus* was detected in one case of severe and one case of non-severe patients respectively. *Mycoplasma* was shown in 36.36% of all patients ([Figure 1C](#f0001){ref-type="fig"}). There was some difference in microbial composition in upper airway between severe and non-severe cases. In non-severe patients, the proportion of *Corynebacterium* was higher (47.22% vs.12.5%) ([Figure 1A](#f0001){ref-type="fig"}), while *Human gamma herpesvirus 4* was lower (30.55% vs. 75%) ([Figure 1B](#f0001){ref-type="fig"}), compared with severe ones. *SARS-CoV-2* declined types of bacteria but increased types of other viruses in upper airway in severe COVID-19 patients in a way.Figure 1The microbial composition of upper airway in patients with *SARS-CoV-2* infection.**Notes:** The percentage of cases with different kinds of bacteria (**A**), virus (**B**), fungus and atypical pathogens (**C**) detected by next generation sequencing of nasopharyngeal test paper was shown in this figure. \*P\<0.05, there was significant difference between severe and non-severe groups.

Discussion {#s0004}
==========

The influence of the *SARS-CoV-2* on the microbial environment of airway mucosa is not clear. Due to the highly infectious characteristics of *SARS-CoV-2*, it is difficult to obtain the secretion samples from lower airway. There are many common normal parasitic bacteria in the upper respiratory tract. Common bacteria have *aureus, coagulase negative staphylococcus, pulmonary chain, group A streptococcus, enterococcus, neisseria meningitis, diphtheria corynebacterium* and so on. And the common fungus is *Candida albicans*.[@cit0003] We studied the influence of SARS-COV-2 on the microbial environment of upper airway mucosa by analyzing the microbial composition of upper respiratory tract of COVID-19 patients. Particularly for severe/critical patients, in which lymphocyte declining and immune function inhibition are obvious, we should pay more attention to some opportunistic infections. For example, combining infection of *Human gamma herpesvirus 4* had been found both in nasopharyngeal test paper and blood samples of 2 critical patients by NGS, accompanying with *SARS-CoV-2* infection.
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